Boston Scientific shares slid as softer-than-expected sales momentum raised questions about hospital procedural volumes and medtech demand.

Boston Scientific trimmed its annual guidance for a second time, citing fallout from a recent cyber incident alongside persistent operational friction across global healthcare markets.